Premium
Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions
Author(s) -
Aoki K. R.,
Guyer B.
Publication year - 2001
Publication title -
european journal of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.881
H-Index - 124
eISSN - 1468-1331
pISSN - 1351-5101
DOI - 10.1046/j.1468-1331.2001.00035.x
Subject(s) - toxin , neurotoxin , botulinum toxin , medicine , serotype , clostridium botulinum , botulinum neurotoxin , pharmacology , potency , botulism , microbiology and biotechnology , virology , biology , biochemistry , anesthesia , in vitro
Botulinum toxin type A is an important therapeutic agent for the treatment of movement and other disorders. As the clinical uses of botulinum toxin type A expand, it is increasingly important to understand the biochemical and pharmacological actions of this toxin, as well as those of other botulinum toxin serotypes (B‐G). Botulinum neurotoxin serotypes exhibit differences in neurotoxin complex protein size, percentage of neurotoxin in the activated or nicked form, intracellular protein target, and potency. These properties differ even between preparations that contain the same botulinum toxin serotype due to variations in product formulations. As demonstrated in preclinical and clinical studies, these differences result in a unique combination of efficacy, duration of action, safety, and antigenic potential for each botulinum neurotoxin preparation.